Stonebridge Capital Advisors LLC Gilead Sciences, Inc. Transaction History
Stonebridge Capital Advisors LLC
- $1.19 Billion
- Q3 2024
A detailed history of Stonebridge Capital Advisors LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Stonebridge Capital Advisors LLC holds 139,616 shares of GILD stock, worth $13.7 Million. This represents 0.98% of its overall portfolio holdings.
Number of Shares
139,616
Previous 134,864
3.52%
Holding current value
$13.7 Million
Previous $9.25 Million
26.47%
% of portfolio
0.98%
Previous 0.82%
Shares
30 transactions
Others Institutions Holding GILD
# of Institutions
1,968Shares Held
996MCall Options Held
10.5MPut Options Held
9.85M-
Black Rock Inc. New York, NY121MShares$11.8 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA115MShares$11.3 Billion0.18% of portfolio
-
Capital World Investors Los Angeles, CA76.5MShares$7.5 Billion1.03% of portfolio
-
Capital Research Global Investors Los Angeles, CA61.8MShares$6.06 Billion1.12% of portfolio
-
State Street Corp Boston, MA60.2MShares$5.9 Billion0.21% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $123B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...